CO5560551A2 - Composiciones farmaceuticas para el tratamiento del asma - Google Patents

Composiciones farmaceuticas para el tratamiento del asma

Info

Publication number
CO5560551A2
CO5560551A2 CO04012909A CO04012909A CO5560551A2 CO 5560551 A2 CO5560551 A2 CO 5560551A2 CO 04012909 A CO04012909 A CO 04012909A CO 04012909 A CO04012909 A CO 04012909A CO 5560551 A2 CO5560551 A2 CO 5560551A2
Authority
CO
Colombia
Prior art keywords
mometasone furoate
formoterol fumarate
inhalation
amount
suspension formulation
Prior art date
Application number
CO04012909A
Other languages
English (en)
Spanish (es)
Inventor
Joel A Sequeira
A Sharpe
John L Hart
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5560551(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5560551A2 publication Critical patent/CO5560551A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO04012909A 2001-08-28 2004-02-16 Composiciones farmaceuticas para el tratamiento del asma CO5560551A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28

Publications (1)

Publication Number Publication Date
CO5560551A2 true CO5560551A2 (es) 2005-09-30

Family

ID=23224164

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04012909A CO5560551A2 (es) 2001-08-28 2004-02-16 Composiciones farmaceuticas para el tratamiento del asma

Country Status (26)

Country Link
US (3) US20030114428A1 (enExample)
EP (3) EP1420759B1 (enExample)
JP (3) JP2005502675A (enExample)
KR (1) KR100970531B1 (enExample)
CN (2) CN101856362A (enExample)
AR (1) AR036358A1 (enExample)
AT (2) ATE503461T1 (enExample)
AU (1) AU2002313828B2 (enExample)
BR (1) BR0212089A (enExample)
CA (1) CA2457926A1 (enExample)
CO (1) CO5560551A2 (enExample)
CY (2) CY1109212T1 (enExample)
DE (2) DE60239648D1 (enExample)
DK (2) DK2092935T3 (enExample)
ES (3) ES2325316T3 (enExample)
HU (1) HUP0401514A3 (enExample)
MX (1) MXPA04001875A (enExample)
NO (1) NO20041277L (enExample)
NZ (1) NZ530987A (enExample)
PE (1) PE20030390A1 (enExample)
PL (1) PL209640B1 (enExample)
PT (2) PT1420759E (enExample)
SI (2) SI1420759T1 (enExample)
TW (1) TWI324934B (enExample)
WO (1) WO2003020253A2 (enExample)
ZA (1) ZA200401419B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
EP1542753B1 (en) * 2002-08-23 2007-02-07 Schering Corporation Pharmaceutical compositions
AU2003265639A1 (en) * 2002-08-27 2004-03-19 Schering Corporation Process for producing metered dose inhaler formulations
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
AU2004285447A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical compositions
ES2426957T3 (es) * 2004-01-21 2013-10-28 Merck Sharp & Dohme Corp. Procedimiento de tratamiento de rinosinusitis aguda
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
CA2581999C (en) * 2004-10-12 2013-04-23 Generics (Uk) Limited Preparation of suspension aerosol formulations
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
CA2641616A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
WO2008097233A1 (en) * 2007-02-09 2008-08-14 Schering Corporation Stable pharmaceutical drug aerosols
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
JP2011509936A (ja) * 2008-01-10 2011-03-31 シェーリング コーポレイション 吸入薬物製品、システムおよび使用
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
WO2010112358A2 (de) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh Verfahren zur beschichtung einer oberfläche eines bauteils
WO2010133294A2 (de) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalationseinrichtung und zerstäuber
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SMT202000077T1 (it) * 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064164A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
ES2487634T3 (es) * 2009-12-07 2014-08-22 Raptor Therapeutics Inc. Formulaciones de 4-metilpirazol
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
HUE042556T2 (hu) 2011-10-11 2019-07-29 Chiesi Farm Spa Zsírsavval bevont béta-agonista kristályos mikrorészecskéi
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
MX361286B (es) 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
KR102443737B1 (ko) 2014-05-07 2022-09-19 베링거 인겔하임 인터내셔날 게엠베하 컨테이너, 분무기 및 사용 방법
EP3928818B1 (en) 2014-05-07 2023-02-01 Boehringer Ingelheim International GmbH Nebulizer and container
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
CN106573082B (zh) 2014-06-30 2020-01-17 普罗沃锐斯科学有限公司 用于确定药物的递送剂量的量和均匀性的采样装置及相关方法
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
ES2866175T3 (es) 2015-12-04 2021-10-19 Mexichem Fluor Sa De Cv Composición farmacéutica
WO2017156287A1 (en) 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
WO2021219495A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN116583316A (zh) 2020-10-15 2023-08-11 普罗沃锐斯科学有限公司 用于吸入器测试的系统和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1992022288A1 (en) * 1991-06-10 1992-12-23 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
ATE202936T1 (de) * 1996-08-29 2001-07-15 Schering Corp Chlorfluorkohlenwasserstoff freie aerosol- arzneizubereitungen enthaltend mometasonfuroat
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
EP1133301A1 (en) * 1998-11-26 2001-09-19 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
CN1406124A (zh) * 2000-01-20 2003-03-26 巴斯利尔药物股份公司 鼻给药的环肽组合物
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
PL368897A1 (en) 2005-04-04
JP2005502675A (ja) 2005-01-27
JP2009185075A (ja) 2009-08-20
CA2457926A1 (en) 2003-03-13
US20100143269A1 (en) 2010-06-10
AU2002313828B2 (en) 2005-09-08
ATE430555T1 (de) 2009-05-15
KR20040031002A (ko) 2004-04-09
DK1420759T3 (da) 2009-08-03
HK1060972A1 (en) 2004-09-03
ES2325316T3 (es) 2009-09-01
CN1649568B (zh) 2010-10-27
JP2010138184A (ja) 2010-06-24
PT1420759E (pt) 2009-06-30
ES2389480T3 (es) 2012-10-26
MXPA04001875A (es) 2004-06-15
CY1109212T1 (el) 2014-07-02
NZ530987A (en) 2006-08-31
HUP0401514A3 (en) 2012-08-28
EP1420759B1 (en) 2009-05-06
BR0212089A (pt) 2004-08-03
PT2092935E (pt) 2011-05-31
SI1420759T1 (sl) 2009-10-31
KR100970531B1 (ko) 2010-07-16
EP2092935B1 (en) 2011-03-30
WO2003020253A3 (en) 2003-05-22
ATE503461T1 (de) 2011-04-15
US20030114428A1 (en) 2003-06-19
ZA200401419B (en) 2005-01-26
CN1649568A (zh) 2005-08-03
DE60232251D1 (de) 2009-06-18
EP2092935A1 (en) 2009-08-26
DK2092935T3 (da) 2011-07-18
CY1111726T1 (el) 2015-10-07
SI2092935T1 (sl) 2011-07-29
HUP0401514A2 (hu) 2004-12-28
US20050147565A1 (en) 2005-07-07
DE60239648D1 (de) 2011-05-12
EP2319494A1 (en) 2011-05-11
HK1128428A1 (en) 2009-10-30
TWI324934B (en) 2010-05-21
WO2003020253A2 (en) 2003-03-13
EP1420759A2 (en) 2004-05-26
JP5170789B2 (ja) 2013-03-27
AR036358A1 (es) 2004-09-01
HK1151987A1 (en) 2012-02-17
PE20030390A1 (es) 2003-04-24
ES2361805T3 (es) 2011-06-22
CN101856362A (zh) 2010-10-13
NO20041277L (no) 2004-03-26
EP2319494B1 (en) 2012-06-13
PL209640B1 (pl) 2011-09-30

Similar Documents

Publication Publication Date Title
CO5560551A2 (es) Composiciones farmaceuticas para el tratamiento del asma
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
AR021922A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos, budesonido y formoterol.
ES2180592T3 (es) Formulaciones en aerosol libres de clorofluorocarbonos.
DK0616525T3 (da) Medikamenter
DE60114571D1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
CY1110136T1 (el) Συνθεσεις ξηρης σκονης με βελτιωμενη διασπαρσιμοτητα
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
CL2022002235A1 (es) Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada
BR0110139A (pt) Formulações farmacêuticas para inaladores de pó seco
BR0116396A (pt) Recipiente, inalador de dosagem medida, método de tratamento da asma ou copd, e, embalagem
CO4940408A1 (es) Composicion de aerosol farmaceutico
ATE391501T1 (de) Aerosoldosiergeräte für delta 9 tetrahydrocannabinol (delta 9 thc)zusammensetzungen und verwendungsverfahren
SE9802073D0 (sv) New use
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
ATE220327T1 (de) Pulmonale abgabe von aktiven fragmenten des parathormons
BR9916865A (pt) Composição farmacêutica em aerossol contendohfa 227 e hfa 134a
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
DE60216588D1 (de) Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
ES2134634T3 (es) Composiciones farmaceuticas y dispositivos para su administracion.
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.

Legal Events

Date Code Title Description
FC Application refused